Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

Journal of Clinical Investigation

Volumn 112, Issue 12, 2003, Pages 1821-1830

  Xu, Haiyan ^a   Barnes, Glenn T ^a   Yang, Qing ^a   Tan, Guo ^a   Yang, Daseng ^a   Chou, Chieh J ^a   Sole, Jason ^a   Nichols, Andrew ^a   Ross, Jeffrey S ^a   Tartaglia, Louis A ^a   Chen, Hong ^a,b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FATTY ACID; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION REGULATION; GIANT CELLS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; INSULIN RESISTANCE; LYMPHOCYTES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MODELS, BIOLOGICAL; NEUTROPHILS; OBESITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; THIAZOLIDINEDIONES; TIME FACTORS; UP-REGULATION;

EID: 9144223683     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200319451     Document Type: Article

References (52)

1. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:87-91.
2. Hotamisligil, G.S., and Spiegelman, B.M. 1994. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 43:1271-1278.
3. Uysal, K.T., Wiesbrock, S.M., Marino, M.W., and Hotamisligil, G.S. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 389:610-614.
4. Uysal, K.T., Wiesbrock, S.M., and Hotamisligil, G.S. 1998. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediatad insulin resistance in genetic obesity. Endocrinology. 139:4832-4838.
5. Ventre, J., et al. 1997. Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes. 46:1526-1531.
6. Moller, D.E. 2000. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 11:212-217.
7. Sattipy, P., and Loskutoff, D.J. 2003. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 100:7265-7270.
8. Pickup, J.C., and Crook, M.A. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 41:1241-1248.
9. Grimble, R.F. 2002. Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care. 5:551-559.
10. Pickup, J.C., Mattock, M.B., Chusney, G.D., and Burt, D. 1997. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40:1286-1292.
11. Festa, A., et al. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 102:42-47.
12. Baron, S.H. 1982. Salicylates as hypoglycemic agents. Diabetes Care. 5:64-71.
13. Yuan, M., et al. 2001. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 293:1673-1677.
14. Hundal, R.S., et al. 2002. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109:1321-1326. doi:10.1172/JCI200214955.
15. Hirosumi, J., et al. 2002. A central role for JNK in obesity and insulin resistance. Nature. 420:333-336.
16. Xu, H., Hirosumi, J., Uysal, K.T., Guler, A.D., and Hotamisligil, G.S. 2002. Exclusive action of transmembrane TNF alpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology. 143:1502-1511.
17. Stahl, A., et al. 1999. Identification of the major intestinal fatty acid transport protein. Mol. Cell. 4:299-308.
18. Soukas, A., Cohen, P., Socci, N.D., and Friedman, J. M. 2000. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 14:963-980.
19. Yoshida, S., Setoguchi, M., Higuchi, Y., Akizuki, S., and Yamamoto, S. 1990. Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage. Int. Immunol. 2:585-591.
20. Wolpe, S.D., et al. 1988. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J. Exp. Med. 167:570-581.
21. Yoshimura, T., et al. 1989. Human monocyte chemoatttactant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett. 244:487-493.
22. Pytela, R. 1988. Amino acid sequence of the murine Mac-1 alpha chain reveals homology with the integrin family and an additional domain related to von Willebrand factor. EMBO J. 7:1371-1378.
23. McKnight, A.J., et al. 1996. Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family. J. Biol. Chem. 271:486-489.
24. Holness, C.L., da Silva, R.P., Fawcett, J., Gordon, S., and Simmons, D.L. 1993. Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family. J. Biol. Chem. 268:9661-9666.
25. O'Rourke, L., Gronning, L.M., Yeaman, S.J., and Shepherd, P.R. 2002. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J. Biol. Chem. 277:42557-42562.
26. Charriete, G., et al. 2003. Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem. 278:9850-9855.
27. Goldsby, R.A., Kindt, T.J., and Osborne, B.A. 2000. Kuby immunology. 4th Edition. W.H. Freeman and Co. New York, New York, USA. 371-393.
28. Spiegelman, B.M. 1998. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:507-514.
29. Lowell, B.B. 1999. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 99:239-242.
30. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:79-82.
31. Jiang, C., Ting, A.T., and Seed, B. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:82-86.
32. Marx, N., Libby, P., and Plutzky, J. 2001. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J. Cardiovasc. Risk. 8:203-210.
33. Li, A.C., et al. 2000. Peroxisome proliferator-activated receptor Γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106:523-531.
34. Chawla, A., et al. 2001. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7:48-52.
35. Moore, K.J., et al. 2001. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 7:41-47.
36. Klappacher, G.W., and Glass, C.K. 2002. Roles of peroxisome proliferator-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages. Curr. Opin. Lipidol. 13:305-312.
37. Hotta, K., et al. 2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20:1595-1599.
38. Ouchi, N., et al. 1999. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 100:2473-2476.
39. Ouchi, N., et al. 2001. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 103:1057-1063.
40. Damerau, B. 1987. Biological activities of complement-derived peptides. Rev. Physiol. Biochem. Pharmacol. 108:151-206.
41. Koistinen, H.A., et al. 2001. Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler. Thromb. Vasc. Biol. 21:1034-1039.
42. Choy, L.N., Rosen, B.S., and Spiegelman, B.M. 1992. Adipsin and an endogenous pathway of complement from adipose cells. J. Biol. Chem. 267:12736-12741.
43. Boggs, R.D., et al. 1998. Increased expression of complement component C3 in the plasma of obese Zucker fa and LA/N fa(f) rats compared with their lean counterparts. Obes. Res. 6:361-367.
44. Huang, D.R., Wang, J., Kivisakk, P., Rollins, B.J., and Ransohoff, R.M. 2001. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193:713-726.
45. Hrnciar J., et al. 1999. Relation between cytokines (TNF-alpha, IL-1 and 6) and homocysteine in android obesity and the phenomenon of Insulin resistance syndromes. Vnitr. Lek. 45:11-16.
46. Amrani, A., et al. 1996. Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage. J. Endocrinol. 148:139-148.
47. Fried, S.K., Bunkin, D.A., and Greenberg, A.S. 1998. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83:847-850.
48. McGarry, J.D. 1992. What if Minkowski had been ageusic? An alternative angle on diabetes. Science. 258:766-770.
49. Ruderman, N.B., Saha, A.K., Vavvas, D., and Witters, L.A. 1999. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. 276:E1-E18.
50. Krssak, M., et al. 1999. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 42:113-116.
51. Yu, C., et al. 2002. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277:50230-50236.
52. Shulman, G.I. 2000. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106:171-176.